USD 1.5
(0.67%)
Year | Gross Profit | Gross Profit Growth |
---|---|---|
2024 | -759.01 Thousand USD | -1.54% |
2023 | -747.52 Thousand USD | -3.35% |
2022 | -723.32 Thousand USD | -2.67% |
2021 | -704.53 Thousand USD | -0.69% |
2020 | -699.72 Thousand USD | -0.55% |
2019 | -695.91 Thousand USD | -2.33% |
2018 | -680.05 Thousand USD | -2.58% |
2017 | -662.95 Thousand USD | -0.52% |
2016 | -659.54 Thousand USD | 0.0% |
2015 | - USD | 0.0% |
2014 | - USD | 0.0% |
2013 | - USD | 0.0% |
2012 | - USD | 0.0% |
2011 | - USD | 0.0% |
2010 | - USD | 0.0% |
2009 | - USD | 0.0% |
2008 | - USD | 0.0% |
2007 | - USD | 0.0% |
2006 | - USD | 0.0% |
2005 | - USD | 0.0% |
Year | Gross Profit | Gross Profit Growth |
---|---|---|
2024 Q1 | -189.12 Thousand USD | -0.13% |
2024 Q4 | -190.6 Thousand USD | -0.34% |
2024 Q3 | -189.95 Thousand USD | -0.33% |
2024 Q2 | -189.33 Thousand USD | -0.11% |
2023 Q3 | -188.32 Thousand USD | -0.75% |
2023 Q4 | -188.88 Thousand USD | -0.3% |
2023 Q2 | -186.92 Thousand USD | -1.92% |
2023 Q1 | -183.4 Thousand USD | 2.42% |
2023 FY | -747.52 Thousand USD | -3.35% |
2022 Q1 | -176.42 Thousand USD | -0.15% |
2022 FY | -723.32 Thousand USD | -2.67% |
2022 Q4 | -187.95 Thousand USD | -3.52% |
2022 Q2 | -177.38 Thousand USD | -0.55% |
2022 Q3 | -181.55 Thousand USD | -2.35% |
2021 Q2 | - USD | 0.0% |
2021 Q3 | -176.14 Thousand USD | 0.0% |
2021 Q1 | - USD | 0.0% |
2021 Q4 | -176.16 Thousand USD | -0.01% |
2021 FY | -704.53 Thousand USD | -0.69% |
2020 Q4 | - USD | 0.0% |
2020 FY | -699.72 Thousand USD | -0.55% |
2020 Q1 | - USD | 0.0% |
2020 Q2 | - USD | 0.0% |
2020 Q3 | - USD | 0.0% |
2019 Q2 | - USD | 0.0% |
2019 Q3 | - USD | 0.0% |
2019 FY | -695.91 Thousand USD | -2.33% |
2019 Q4 | - USD | 0.0% |
2019 Q1 | - USD | 0.0% |
2018 FY | -680.05 Thousand USD | -2.58% |
2018 Q4 | - USD | 0.0% |
2018 Q3 | - USD | 0.0% |
2018 Q2 | - USD | 0.0% |
2018 Q1 | - USD | 0.0% |
2017 Q4 | - USD | 0.0% |
2017 FY | -662.95 Thousand USD | -0.52% |
2017 Q1 | - USD | 0.0% |
2017 Q2 | - USD | 0.0% |
2017 Q3 | - USD | 0.0% |
2016 Q3 | - USD | 0.0% |
2016 Q2 | - USD | 0.0% |
2016 FY | -659.54 Thousand USD | 0.0% |
2016 Q4 | - USD | 0.0% |
2016 Q1 | - USD | 0.0% |
2015 Q4 | - USD | 0.0% |
2015 Q2 | - USD | 0.0% |
2015 FY | - USD | 0.0% |
2015 Q3 | - USD | 0.0% |
2015 Q1 | - USD | 0.0% |
2014 Q3 | - USD | 0.0% |
2014 FY | - USD | 0.0% |
2014 Q4 | - USD | 0.0% |
2014 Q2 | - USD | 0.0% |
2014 Q1 | - USD | 0.0% |
2013 Q2 | - USD | 0.0% |
2013 Q4 | - USD | 0.0% |
2013 Q3 | - USD | 0.0% |
2013 FY | - USD | 0.0% |
2013 Q1 | - USD | 0.0% |
2012 Q1 | - USD | 0.0% |
2012 FY | - USD | 0.0% |
2012 Q4 | - USD | 0.0% |
2012 Q3 | - USD | 0.0% |
2012 Q2 | - USD | 0.0% |
2011 Q3 | - USD | 0.0% |
2011 Q1 | - USD | 0.0% |
2011 FY | - USD | 0.0% |
2011 Q2 | - USD | 0.0% |
2011 Q4 | - USD | 0.0% |
2010 Q1 | - USD | 0.0% |
2010 Q4 | - USD | 0.0% |
2010 Q3 | - USD | 0.0% |
2010 Q2 | - USD | 0.0% |
2010 FY | - USD | 0.0% |
2009 Q2 | - USD | 0.0% |
2009 Q4 | - USD | 0.0% |
2009 Q1 | - USD | 0.0% |
2009 FY | - USD | 0.0% |
2009 Q3 | - USD | 0.0% |
2008 Q3 | - USD | 0.0% |
2008 Q2 | - USD | 0.0% |
2008 FY | - USD | 0.0% |
2008 Q4 | - USD | 0.0% |
2008 Q1 | - USD | 0.0% |
2007 FY | - USD | 0.0% |
2007 Q2 | - USD | 0.0% |
2007 Q3 | - USD | 0.0% |
2007 Q4 | - USD | 0.0% |
2007 Q1 | - USD | 0.0% |
2006 Q4 | - USD | 0.0% |
2006 FY | - USD | 0.0% |
2006 Q3 | - USD | 0.0% |
2006 Q2 | - USD | 0.0% |
2006 Q1 | - USD | 0.0% |
2005 FY | - USD | 0.0% |
Name | Gross Profit | Gross Profit Difference |
---|---|---|
AIM ImmunoTech Inc. | 160 Thousand USD | 574.384% |
Ampio Pharmaceuticals, Inc. | -250 Thousand USD | -203.606% |
Armata Pharmaceuticals, Inc. | -29.24 Million USD | 97.404% |
Actinium Pharmaceuticals, Inc. | -709 Thousand USD | -7.054% |
Azitra, Inc. | 260.45 Thousand USD | 391.423% |
Can-Fite BioPharma Ltd. | 743 Thousand USD | 202.155% |
Chromocell Therapeutics Corporation | -2.57 Million USD | 70.574% |
Calidi Biotherapeutics, Inc. | -1.25 Million USD | 39.569% |
CEL-SCI Corporation | -3.95 Million USD | 80.825% |
iBio, Inc. | -1.02 Million USD | 25.95% |
Lineage Cell Therapeutics, Inc. | 8.27 Million USD | 109.173% |
MAIA Biotechnology, Inc. | - USD | Infinity% |
Matinas BioPharma Holdings, Inc. | -13.39 Million USD | 94.333% |
Navidea Biopharmaceuticals, Inc. | -119.29 Thousand USD | -536.25% |
NovaBay Pharmaceuticals, Inc. | 7.89 Million USD | 109.614% |
Oragenics, Inc. | -15.45 Million USD | 95.088% |
BiomX Inc. | -1.22 Million USD | 38.191% |
BiomX Inc. | -1.22 Million USD | 38.191% |
Protalix BioTherapeutics, Inc. | 42.51 Million USD | 101.785% |
Palatin Technologies, Inc. | 4.39 Million USD | 117.28% |
Scorpius Holdings, Inc. | -2.21 Million USD | 65.755% |